Tags : Multiple Cancer Indications

Centus Biotherapeutics’ Equidacent (bevacizumab, biosimilar) Receives CHMP’s Positive Opinion for

Shots: The EMA’s CHMP has adopted a positive opinion recommending the MAA of Centus’ Equidacent (bevacizumab), a biosimilar to Roche’s Avastin to treat carcinoma of the colon or rectum, breast cancer, NSCLC, RCC, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix Equidacent will be available as 25 mg/ml as the […]Read More

Mount Sinai Signs a Multi-Year Collaboration with Harbour BioMed to

Shots: The companies signed a multi-year, multifaceted collaboration to develop novel Ab to treat & prevent various diseases including oncology and immunology The collaboration leverages H2L2 Harbour Mice platform to generate mAb against SARS CoV 2 – COVID-19 and allow HBM to access Mount Sinai’s research-driven from its clinical practices The collaboration demonstrated HBM’s dedication […]Read More

Teva Canada’s Herzuma (biosimilar, trastuzumab) Receives Health Canada Approval for

Shots: Health Canada has granted notice of compliance for Teva Canada’s Herzuma for the treatment of early breast cancer (EBC), metastatic breast cancer (MBC) and metastatic gastric cancer (MGC) in Canada The Health Canada NOC is based on efficacy, safety, quality, immunogenicity, PK/PD data from non-clinical and clinical studies, demonstrating that Herzuma and Herceptin has […]Read More